AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03012503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioFreeze
Description: The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
Study NCT03012503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
Study NCT01683929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sweetner
Description: The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR \& BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire.
Study NCT01849627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-ED
Description: This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.
Study NCT01849627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Balance
Description: Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
Study NCT04498091 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological data
Description: Biological data
Study NCT03742557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV
Description: Ketamine 0.5 mg/kg IV
Study NCT03742557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV
Description: Ketamine 0.5 mg/kg IV
Study NCT01615939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 0.625% with epinephrine 1:300,000
Study NCT01615939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
Study NCT00821548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrostimulation
Description: Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
Study NCT02947321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular Nerve RFA
Description: Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. RFA probes will be placed and connected to the RFA generator and the generator is activated. The RFA is performed.
Study NCT02947321 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Genicular Nerve RFA
Description: Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
Study NCT04498091 — intervention group
Intervention type: OTHER
Intervention: Clinical data
Description: Clinical data
Study NCT01820013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customised Dynamic Elastomeric fabric Orthoses
Description: Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
Study NCT00570830 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Retisert (fluocinolone acetonide implant)
Description: Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
Study NCT02397577 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Solid test meal, liquid test meal on two separate occations
Description: 13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
Study NCT01820013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Serola Sacroiliac Belt
Description: Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
Study NCT05182281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration and Infrared Therapy
Description: Patients in the whole body vibration and infrared group received vibration therapy with a frequency of 60 Hz and amplitude of 0.5-2 mm and infrared therapy at a wavelength of 550-950 nm. Whole body vibration and infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
Study NCT05182281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared Therapy
Description: Patients in infrared therapy group received infrared therapy at a wavelength of 550-950 nm.Infrared treatment were applied with the Power Andullator (HHP, CE0197, Germany) device.
Study NCT05182281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classical Treatment
Description: 1000 mg Ca and 880 IU vitamin D treatment were given
Study NCT02435953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
Study NCT02435953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
Study NCT02435953 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
Study NCT02085967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin 600 mg
Study NCT02085967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole 200 mg
Study NCT02085967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam 2 mg with bupropion 75 mg
Study NCT02085967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006
Study NCT02941081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHAT
Description: 1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
Study NCT02941081 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate
Description: 1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
Study NCT02781844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mcg rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.
Study NCT02781844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mcg rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
Study NCT02941081 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
Study NCT00812708 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morcher iris diaphragm implantation
Description: Surgical implantation of Morcher iris device(s)
Study NCT01632696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-124 PGN650 for PET/CT
Description: I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
Study NCT04524780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracardiac echocardiography
Description: 30 patients use intracardiac echocardiography to guide left atrial appendage occluder device, 30 patients use radiography to guide left atrial appendage occluder device.
Study NCT04461275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS 2.0
Description: ERAS 2.0 accelerated protocol with adequate fluid management, pain control and truly minimally invasive surgery (intracorporeal anastomosis)
Study NCT02781844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mcg rhPTH(1-84)
Description: Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
Study NCT01082016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Enhancement Program (SEP)
Description: Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
Study NCT01980563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Study NCT00321373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate Influenza Vaccine GSK1247446A - 2 different formulations
Description: Single dose, Intramuscular injection
Study NCT00321373 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluarixTM
Description: Single dose, Intramuscular injection
Study NCT00918580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumoccocal Conjugate Vaccine
Description: 2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
Study NCT01076426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-biotics
Description: Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
Study NCT01980563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined monitoring
Study NCT01105481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride add-on
Description: At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
Study NCT01105481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo add-on
Description: For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
Study NCT03390946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poor responder group adjuvant chemotherapy
Description: Poor responder group (necrosis ≤ 90%)~: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~B. Resection of tumor~C. Adjuvant chemotherapy~1. Poor responder group (necrosis ≤ 90%)~   * week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~2. Good responder group (necrosis > 90%)~   * week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin
Study NCT03390946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Good responder group adjuvant chemotherapy
Description: Good responder group (necrosis > 90%)~: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin
Study NCT03021785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TK001
Description: TK001 will be administered intravitreal injection.
Study NCT01076426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oligosaccharide
Description: oligosaccharide one pack per day
Study NCT03897764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative superior hypogastric plexus block
Description: SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.
Study NCT04240535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 50 UNT [Botox Cosmetic]
Description: Injections to the Depressor Anguli Oris
Study NCT04240535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OnabotulinumtoxinA 50 UNT [Botox Cosmetic]
Description: Injections to the Depressor Anguli Oris
Study NCT03897764 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intraoperative superior hypogastric plexus block
Description: SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.
Study NCT04568694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed Lung Transplantation
Description: Transplants with a planned recipient anesthesia start time between 10:00 pm and 6:00 am will be allowed to move to a start time between 6:00 am and 8:00 am at the earliest. Donor lung(s) cross clamp time must occur between 5:00 pm and 4:00 am. Lungs that meet criteria will be transported in the usual fashion in a cooler of ice at 4oC. Upon arrival to NYULH, the lungs will be transferred to cold static preservation at 10oC within a specific incubator located in a NYULH OR (MYTEMP™65HC, Benchmark Scientific).
Study NCT04568694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Lung Transplantation
Description: Reference Therapy
Study NCT01528501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589)
Study NCT04464486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCH Intervention
Description: In addition to receiving usual care from their oncologist and staff, the SCH intervention group will report COVID-19 and cancer-related symptom presence and severity daily into the automated SCH system. Participants in the intervention receive automated self-management support messages for symptoms reported. In addition, COVID-19 symptoms and poorly controlled or worsening cancer symptoms will generate alerts. Based on preset thresholds, alerts automatically generate immediately from the patient's daily call data. The study nurse practitioners (NPs) monitor alerts. The NPs provide follow-up care using the guideline based SCH symptom clinical decision support system. The NPs log into the SCH Alert and Call Data website which displays all of the patients who have called that day and met an alert threshold. The NP calls the patient, delivers symptom management care by phone, and documents care in the patients' electronic health records.
Study NCT03938259 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Description: identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
Study NCT02456415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-MET™ Bioresorbable Bone screw
Description: The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
Study NCT01639781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol rich intervention
Description: Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
Study NCT01639781 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavanol free control
Description: Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
Study NCT05310019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and Electroacupuncture
Description: TThe physiotherapy treatment (50min): warm compress with facial thermal blanket, respiratory muscle mobility training and cervical muscle relaxation, facial lymphatic drainage, start of myolymphokinetic exercises for the orbicularis, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma, release of intraoral adhesions, vacuum therapy at 60 mmHg, active exercises free of mandibular movements, maintenance of mandibular opening with wooden tongue depressors. The electroacupuncture treatment lasting another 30 min. Electroacupuncture treatment lasting another 30min. The repetition time of 1 sec; (F1-10 Hz, F2= 45 Hz; 10 mA). Facial acupuncture needles are disposable with 0.20 mm gauge and 10 mm length. Each needle will be inserted at the indicated points, totaling 10 needles and electrodes will be connected to each one. Electrical stimulation will be performed on the face points: E4, Jiachengjiang (extra point), E5, E6, bilaterally and point CV-24.
Study NCT03710031 — intervention group
Intervention type: OTHER
Intervention: PNS Tracking
Description: Through blood and stool samples the study team will track the interplay among PNS as they relate to diminished QOL. Symptoms tracked include neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota \[(GM) richness and diversity\] and diet (macronutrients: carbohydrates, fats and proteins).
Study NCT00287495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
Study NCT03131583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Day-14\~Day16 qd
Study NCT03131583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Day1 and Day8 qd
Study NCT03131583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: Day3\~Day8 qd
Study NCT02238353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azelastine + fluticasone
Study NCT02238353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05310019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: The physiotherapy treatment protocol will be divided into 6 meetings: warm compress with facial thermal blanket (5min), respiratory muscle mobility training and cervical muscle relaxation (5min) facial lymphatic drainage (10min), start of myolymphokinetic exercises for the orbicularis oris, zygomatic major and minor muscles, upper lip lifter and nose wing, buccinator and platysma (5 min), release of intraoral adhesions (5min) vacuum therapy at 60 mmHg (5min), active exercises free of mandibular movements (5 min), maintenance of mandibular opening with wooden tongue depressors (10min).
Study NCT00730457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX125
Description: Single intramuscular dose
Study NCT03422523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Intravenous drip
Study NCT01347112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: varenicline 1.0 mg dose, twice daily for 12 weeks
Study NCT01347112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill twice daily for 12 weeks
Study NCT03422523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenous drip/or Subcutaneous from cycle 2
Study NCT03422523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous drip/or Subcutaneous from cycle 2
Study NCT03422523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine 1000 mg
Description: intravenous drip